个性化新抗原癌症疫苗：对正在进行的开发计划的临床和商业潜力的分析。
Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs.
发表日期：2023 Sep 18
作者：
Maurice Perrinjaquet, C Richard Schlegel
来源：
DRUG DISCOVERY TODAY
摘要：
新抗原癌症疫苗作为下一代免疫肿瘤学治疗具有巨大潜力，这种治疗方式将癌症疫苗个性化地针对患者的肿瘤抗原，代表了个体化癌症治疗的未来。虽然有几家生物技术公司正在进行开发项目，但目前关于这些创新疗法的商业潜力以及这些产品在获得监管批准后将面临的挑战尚无多少出版物。在本文中，我们对新抗原癌症疫苗开发计划进行了概述，并讨论了这些疗法在上市时所面临的商业环境。版权所有© 2023年。由Elsevier Ltd.出版。
Neoantigen cancer vaccines harbor promise as next-generation immuno-oncology therapies, whereby cancer vaccines are tailored to the patient's tumor antigen and represent the future of personalized cancer therapy. While several biotech companies have ongoing development programs, little has been published about the true commercial potential of these innovative therapies and the challenges these products will face upon regulatory approval. In this paper, we provide an overview of neoantigen cancer vaccine development programs and discuss the commercial environment these therapies will face upon launch.Copyright © 2023. Published by Elsevier Ltd.